United States: Federal Circuit Patent Update - April 2, 2019

Precedential Federal Circuit Opinions

1.                  FOREST LABORATORIES, LLC v. SIGMAPHARM LABORATORIES, LLC [OPINION - PRECEDENTIAL] (2017-2369, 2017-2370, 2017-2372, 2017-2373, 2017-2374, 2017-2375, 2017-2376, 2017-2389, 2017-2412, 2017-2436, 2017-2438, 2017-2440, 2017-2441, 03/14/2019) (PROST, DYKE, MOORE)  

Moore, J.  Vacating and remanding the district court's determinations regarding validity and infringement issues.  This appeal involves multiple Abbreviated New Drug Applications (ANDAs) filed with the Food and Drug Administration by companies seeking to market generic versions of Saphris, a drug product administered sublingually (i.e., dissolved under the tongue).  Regarding the validity issue, the Court remanded for the district court to make an express finding regarding one of the defendants' proposed motivations to combine prior art references that allegedly rendered the claims invalid as obvious.  The Court also affirmed the district court's determination that appellants had not established invalidity for lack of written description by clear and convincing evidence.  Regarding the infringement issue, the Court held that the district court had found no infringement based on an incorrect claim construction that limited the asserted claims to the treatment of certain disorders.  The Court held that the claims were not limited only to treating certain disorders, but also covered treating certain symptoms, and remanded for further consideration of the infringement issue in view of the corrected claim construction.


Moore, J.  Reversing and remanding the district court's determination, on a motion for judgment on the pleadings, that the plaintiff's six asserted patents related to dietary supplements were invalid for lack of patentable subject matter under 35 U.S.C. § 101.  The Court explained that in deciding a motion for judgment on the pleadings a court must accept the plaintiff's allegations that the claims did not recite conventional subject matter.  The Court also accepted the plaintiff's proposed claim constructions for purposes of evaluating the pleadings, noting that neither party had argued for a different construction on appeal.  Applying this standard, the Court held that the plaintiff's complaint had sufficiently pleaded that the claims were directed to patent eligible dietary supplements and methods of treatment. 

Judge Reyna concurred in part and dissented in part, writing that he would have applied a different claim construction than the construction applied by the majority.

3.                  SRI INTERNATIONAL, INC. v. CISCO SYSTEMS, INC. [OPINION - PRECEDENTIAL] (2017-2223, 03/20/2019) (LOURIE, O'MALLEY, STOLL)*  

Stoll, J.  Affirming in part, vacating in part, and remanding the district court's judgment in a patent infringement case regarding network intrusion detection technology.  The Court affirmed the district court's denial of Cisco's motion for summary judgment of patent ineligibility under 35 U.S.C. § 101, finding that the claims were not directed to an abstract idea.  Instead, the Court concluded that the claims "are directed to using a specific technique—using a plurality of network monitors that each analyze specific types of data on the network and integrating reports from the monitors—to solve a technological problem arising in computer networks: identifying hackers or potential intruders into the network."  The Court also affirmed the district court's construction of the claim term "network traffic data" to mean "data obtained from direct examination of network packets."  The Court held that the patentee's statements during reexamination did not amount to a disclaimer of "pre-processing" of network packets.  The Court also affirmed the district court's grant of summary judgment of no anticipation, finding that the prior art at issue did not expressly disclose directly examining network packets as required by the claims.  The Court also affirmed the award of an ongoing royalty.  However, the Court vacated the district court's finding of willfulness, concluding that there was no substantial evidence to support a finding of willfulness prior to when the plaintiff notified the defendant of the asserted patent in 2012.  The Court also vacated the district court's award of attorneys' fees and remanded for recalculation.

Judge Lourie dissented, writing that the claims should have been held invalid under 35 U.S.C. § 101 because they are directed to an abstract idea without an inventive concept.

*WilmerHale represented the defendant on appeal.

4.                  ARCTIC CAT INC. v. GEP POWER PRODUCTS, INC. [OPINION - PRECEDENTIAL] (2018-1520, 2018-1521, 03/26/2019) (PROST, REYNA, TARANTO)  

Taranto, J.  The Court considered two IPR decisions invalidating all claims of two patents directed to a "Power Distribution Module for Personal Recreational Vehicle."  With respect to both patents, the Court affirmed the PTAB's determination that the preambles were not limiting.  However, the Court reversed in part, vacated in part, and remanded one of the IPR decisions because it depended in part on a reference (called the "Boyd" reference) that the PTAB had incorrectly determined to be prior art.  The Court held that the patent owner had shown that claims of the patents at issue were conceived before the Boyd reference and were then diligently reduced to practice.  As a result, Boyd was not prior art.  However, the Court affirmed the PTAB's findings of invalidity with regard to the IPR of the second patent, in which the grounds did not depend on the Boyd reference.

5.                  GRUNENTHAL GMBH v. ALKEM LABORATORIES LIMITED [OPINION - PRECEDENTIAL]  (2017-1153, 2017-2048, 2017-2049, 2017-2050, 03/28/2019) (REYNA, TARANTO, CHEN)  

Reyna, J.  Affirming the district court's judgment in a bench trial involving multiple defendants regarding two patents directed to certain compounds and methods for the treatment of pain.  On appeal, three defendants appealed the judgment that U.S. Patent No. 7,994,364 is not invalid for obviousness or lack of utility.  The Court held that the district court did not clearly err in concluding that the claims were not invalid as obvious, because a person of ordinary skill in the art would not have had a reasonable expectation of success of producing the claimed invention based on the prior art.  The Court also rejected the defendants' argument that the patent lacked utility, finding that there was substantial evidence that the claimed compound is useful for pain relief.  In addition, the plaintiff cross-appealed to challenge the district court's determination that three defendants did not indirectly infringe U.S. Patent No. 8,536,130, which is directed to the treatment of polyneuropathic pain, a type of pain caused by damage to multiple nerves.  The Court affirmed that these defendants were not liable for induced infringement because they not induce others to use the accused medications for the treatment of polyneuropathic pain.  The Court also affirmed that these defendants were not liable for contributory infringement because their medications had substantial non-infringing uses for the treatment of chronic pain conditions that are not polyneuropathic.

6.                  CHARGEPOINT, INC. v. SEMACONNECT, INC. [OPINION - PRECEDENTIAL] (2018-1739, 03/28/2019) (PROST, REYNA, TARANTO)  

Prost, C.J.  Affirming the district court's judgment that all of the asserted patent claims directed to networks of charging stations for electric vehicles were invalid for lack of patentable subject matter under 35 U.S.C. § 101.  The Court explained that the patents are directed to "the abstract idea of communicating over a network for device interaction," applied to network charging stations.  The Court further explained that the claims do not add network connectivity to these charging stations in an unconventional way.  Accordingly, the Court held that the only possible inventive concept was the abstract idea of network connectivity itself, and therefore that the claims were ineligible for patent protection.

7.                  ENDO PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. [OPINION - PRECEDENTIAL] (2017-1240, 2017-1455, 2017-1887, 03/28/2019) (WALLACH, CLEVENGER, STOLL)  

Stoll, J.  Reversing the district court's judgment that a patent directed to pharmaceutical compositions and dosing methods for renal impairment was invalid for lack of patentable subject matter under 35 U.S.C. § 101.  The Court held that the claims are patent eligible because they are "directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome."


Prost, C.J.  Affirming in part, reversing in part, and vacating in part the district court's judgment in a case regarding a patent directed to an emergency kit for repairing vehicle tires deflated by puncture.  The Court vacated the judgment with respect to validity on the ground that the district court improperly restricted the defendant's effort to present relevant evidence of invalidity at trial.  In particular, the Court held that the district court had incorrectly prevented the defendant from relying on two prior art references that had been found not to render the claims obvious in a prior appeal.  The Court explained that its prior mandate foreclosed an invalidity theory based on only those two references but did not preclude the defendant from combining those references with other prior art to challenge validity on remand.  Accordingly, the Court remanded for the district court to conduct a new trial on the issue of validity.  The Court also addressed the remaining issues on appeal in the interest of judicial economy.  The Court affirmed the judgment with respect to infringement and lost profits damages as supported by substantial evidence.  The Court also affirmed the award of a permanent injunction, noting among other things that the parties were direct competitors and that the defendant's infringement had forced the plaintiff to compete against its own patented invention.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions